One of the most widely discussed current policy issues is whether there is a need for an expedited reimbursement policy following the repeal of MCIT. Proponents are promoting TCET in its place. Here, former FDA Commissioner and CMS Administrator Mark McClellan weighs in on this issue, which involves both of his former agencies, along with other challenges facing the industry.Read Article
Stephen Levin has spent nearly 25 years covering the life sciences industry, writing and speaking primarily on medical technology worldwide. Before Levin and his partner, David Cassak, launched Innovation In Medtech, LLC, the parent company of MEDTECH STRATEGIST and MARKET PATHWAYS, along with international conferences, Levin formerly was Editor-in-Chief/Medical Devices at Elsevier Business Intelligence (EBI). At EBI, he directed the editorial coverage for the company’s medtech publications, including IN VIVO, START-UP, MEDTECH INSIGHT, THE GRAY SHEET, and THE SILVER SHEET, along with the content for the Investment In Innovation (IN3) series of medical device partnering conferences.
Prior to joining Windhover, Levin was Senior Counsel to the US Senate Permanent Subcommittee on Investigations, where he directed Senate investigations into a wide variety of areas including health care fraud and abuse, international organized crime, and corruption in federal contracting programs, while also participating in other Senate investigations, including the Whitewater inquiry. Before joining the Subcommittee, Levin was an enforcement and regulatory attorney in the Federal Election Commission’s Office of General Counsel, and also worked at the US Department of Justice. He was formerly an Editor of HEALTH INDUSTRY TODAY, a leading publication in the health care distribution industry.